Previous Close | 34.650 |
Open | 34.800 |
Bid | 34.650 x N/A |
Ask | 34.700 x N/A |
Day's Range | 33.950 - 35.600 |
52 Week Range | 17.440 - 35.600 |
Volume | |
Avg. Volume | 3,573,242 |
Market Cap | 29.621B |
Beta (5Y Monthly) | 0.65 |
PE Ratio (TTM) | 36.91 |
EPS (TTM) | 0.940 |
Earnings Date | Jul 29, 2024 - Aug 02, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that Dr Renu Bhatia is appointed as an Independent Non-executive Director and a member of Technical Committee of the Company with effect from May 13, 2024. Dr Bhatia, a licensed physician, has over 25 years of experience in the healthcare, finance and fintech, and regulatory sectors. She is an experienced board di
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO-2 Phase III clinical trial — HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that its partner Takeda (TSE:4502/NYSE:TAK) received notification that the Com
It is a pleasure to report that the HUTCHMED (China) Limited ( LON:HCM ) is up 35% in the last quarter. But over the...